2021-07-20

Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Dorothy M. Davis Heart and Lung Research Institute, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.; Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Dorothy M. Davis Heart and Lung Research Institute, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.; Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Dorothy M. Davis Heart and Lung Research Institute, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.; Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, College of Medicine, Center for RNA Biology, The Ohio State University, Columbus, Ohio 43210, United States.; TMU Research Center of Cancer Translational Medicine, School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.; TMU Research Center of Cancer Translational Medicine, School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.; Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Dorothy M. Davis Heart and Lung Research Institute, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.; Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, College of Medicine, Center for RNA Biology, The Ohio State University, Columbus, Ohio 43210, United States.; TMU Research Center of Cancer Translational Medicine, School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.; Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Dorothy M. Davis Heart and Lung Research Institute, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.

RNA nanotechnology is the bottom-up self-assembly of nanometer-scale architectures, resembling LEGOs, composed mainly of RNA. The ideal building material should be (1) versatile and controllable in shape and stoichiometry, (2) spontaneously self-assemble, and (3) thermodynamically, chemically, and enzymatically stable with a long shelf life. RNA building blocks exhibit each of the above. RNA is a polynucleic acid, making it a polymer, and its negative-charge prevents nonspecific binding to negatively charged cell membranes. The thermostability makes it suitable for logic gates, resistive memory, sensor set-ups, and NEM devices. RNA can be designed and manipulated with a level of simplicity of DNA while displaying versatile structure and enzyme activity of proteins. RNA can fold into single-stranded loops or bulges to serve as mounting dovetails for intermolecular or domain interactions without external linking dowels. RNA nanoparticles display rubber- and amoeba-like properties and

2021-03-24

Department of Neurology, West Virginia University School of Medicine, Morgantown, WV, USA.; Department of Neurology, University of Missouri Healthcare, Columbia, MO, USA.; B.J. Medical College and Civil hospital, Ahmedabad, India.; Institute of Medicine, Kathmandu, Nepal.; Safdarjung Hospital, India.; Department of Neurology, West Virginia University School of Medicine, Morgantown, WV, USA.; Department of Neurology, West Virginia University School of Medicine, Morgantown, WV, USA.; Department of Neurology, West Virginia University School of Medicine, Morgantown, WV, USA.; Department of Neurology, West Virginia University School of Medicine, Morgantown, WV, USA; West Virginia Clinical Transitional Science, Morgantown, WV, USA. Electronic address: shitiz.sriwastava@hsc.wvu.edu.

OBJECTIVE: To report a unique case and literature review of post COVID-19 associated transverse myelitis and dysautonomia with abnormal MRI and CSF findings. BACKGROUND: Coronavirus disease have been reported to be associated with several neurological manifestations such as stroke, Guillain-Barré syndrome, meningoencephalitis amongst others. There are only few reported cases of transverse myelitis with the novel coronavirus (n-CoV-2) and only one reported case identifying dysautonomia in COVID-19 patient. Here, we identify a COVID-19 patient diagnosed with acute transverse myelitis in addition to dysautonomia following with complete resolution of symptoms. METHOD: A retrospective chart review of a patient diagnosed with post SARS-CoV-2 infection acute transverse myelitis and dysautonomia, and a review of literature of all the reported cases of transverse myelitis and COVID-19, from December 1st, 2019 till December 25th, 2020, was performed. CONCLUSION: To our knowledge, this is the

Army College of Medical Sciences, New Delhi 110010, India.; Department of Neurology, Wayne State University, Detroit, MI 48201, USA.; B.J. Medical College and Civil Hospital, Ahmedabad 380016, India.; Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.; Kathmandu Medical College, Kathmandu 44600, Nepal.; Department of Biostatistics, West Virginia University, Morgantown, WV 26506, USA.; Department of Biostatistics, West Virginia University, Morgantown, WV 26506, USA.; Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA.; West Virginia Clinical and Translational Science Institute, Morgantown, WV 26506, USA.

BACKGROUND: The data on neurological manifestations in COVID-19 patients has been rapidly increasing throughout the pandemic. However, data on CNS and PNS inflammatory disorders in COVID-19 with respect to CSF, serum and neuroimaging markers is still lacking. METHODS: We screened all articles resulting from a search of PubMed, Google Scholar and Scopus, using the keywords "SARS-CoV-2 and neurological complication", "SARS-CoV-2 and CNS Complication" and "SARS-CoV-2 and PNS Complication" looking for transverse myelitis, vasculitis, acute disseminated encephalomyelitis, acute hemorrhagic necrotizing encephalitis (AHNE), cytotoxic lesion of the corpus callosum (CLOCC) and Guillain-Barré syndrome (GBS), published between 1 December 2019 to 15 July 2021. RESULTS: Of the included 106 CNS manifestations in our study, CNS inflammatory disorders included transverse myelitis (17, 14.7%), AHNE (12, 10.4%), ADEM (11, 9.5%), CLOCC/MERS (10, 8.6%) and vasculitis (4, 3.4%). Others were nonspecific

2021-09-28

Zydus Hospital, Ahmedabad, Gujarat, India.; Department of ENT, GCS Medical College, Ahmedabad, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Max Hospital, New Delhi, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; BJ Medical College and Civil Hospital, Ahmedabad, India.; Division of Neurology, Department of Medicine, National University Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Zydus Hospital, Ahmedabad, Gujarat, India.; Division of Neurology, Department of Medicine, National University Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

IMPORTANCE: Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. We evaluated clinical features, predisposing factors, diagnosis and outcomes for mucormycosis among patients with COVID-19 infection. METHODS: This prospective, observational, multi-centre study included 47 consecutive patients with mucormycosis, diagnosed during their course of COVID-19 illness, between January 3 and March 27, 2021. Data regarding demography, underlying medical conditions, COVID-19 illness and treatment were collected. Clinical presentations of mucormycosis, imaging and biochemical characteristics and outcome were recorded. RESULTS: Of the 2567 COVID-19 patients admitted to 3 tertiary centres, 47 (1.8%) were diagnosed with mucormycosis. Mean age was 55 ± 12.8years, and majority suffered from diabetes mellitus (n = 36, 76.6%). Most were not COVID-19 vaccinated (n = 31, 66.0%) and majority (n = 43, 91.5%) had developed